In the letters, sent to Eli Lilly & Co., Novo Nordisk A/S, Pfizer Inc. and others, Trump insisted companies immediately lower ...

An encouraging quarterly earnings report was dampened by a new demand from President Trump.

A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggested big pharma may finally be willing to place ...

Discover AbbVie's standout Q2 2025 earnings insights, with strong Skyrizi & Rinvoq growth, raised revenue guidance, and robust R&D progress driving ...

AbbVie Inc. ABBV reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89. The ...

AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people ...

AbbVie's beat Wall Street's estimates for its top- and bottom-lines in its latest quarter, boosted by sales of Skyrizi and Rinvoq. The North Chicago, Ill., drugmaker said it logged earnings of $938 ...

NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Thursday reported second-quarter earnings of $938 million. The North Chicago, Illinois-based company said it had net income ...

AbbVie Inc (ABBV) is reportedly negotiating to buy Gilgamesh Pharmaceuticals, a private company focusing on mental health treatments, for roughly $1 billion. The discussions, highlighted by Bloomberg, ...

AbbVie Inc. (NYSE: ABBV) is reportedly negotiating the acquisition of Gilgamesh Pharmaceuticals, a privately held mental ...

AbbVie on Wednesday said the Phase 3 study evaluating the safety and efficacy of Rinvoq in adults and adolescents with severe alopecia areata met its primary endpoint of 80% or more scalp hair ...

AbbVie's trading session ended on a bearish note, with shares dipping to $187.64, nearly $4 below the day's high. The stock ...